A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2017
At a glance
- Drugs ANAVEX 2-73 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Anavex Life Sciences
- 04 Nov 2017 According to an Anavex Life Sciences media release, data from this trial were presented at the 2017 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
- 17 Nov 2014 Full results were presented at CNS Summit 2014, according to an Anavex Life Sciences media release.
- 17 Nov 2014 Results published in Anavex Life Sciences media release.